Exelixis (EXEL) EBITDA Margin (2010 - 2026)
Exelixis (EXEL) recorded EBITDA Margin of 40.62% in Q2 2027, up 1.75 percentage points from 38.88% a year earlier but down 1.66 percentage points from the prior quarter.
Powered by 
Analysis
Exelixis (EXEL) EBITDA Margin (2010 - 2026) Analysis & Trends
On a TTM basis, Exelixis' EBITDA Margin came in at 41.04% as of Jul 3, 2026, up 8.33 percentage points year-over-year; for FY2026, it came in at 38.84%, up 9.64 percentage points from FY2025.
- Annual EBITDA Margin has a five-year change of +17.92 percentage points (FY2021 to FY2026).
- Across earlier years, EBITDA Margin came in at 29.21% in FY2025, 10.74% in FY2023 (-3.06 pp) and 13.80% in FY2022 (-7.12 pp).
- Quarterly EBITDA Margin has ranged from 8.43% in Q1 2025 to 44.45% in Q2 2025 over the past five years.
- On a year-over-year basis, EBITDA Margin has increased for four consecutive quarters, with an average year-over-year change of +9.09 percentage points over the last six quarters.
- Per Business Quant, the preceding three quarters came in at 42.29% (Q1 2027), 40.45% (Q4 2026) and 40.81% (Q3 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 39.10% |
| 10 | Exelixis | 14.54 Bn | 10.87 Bn | 608.03 Mn | 40.62% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 40.62% |
| Apr 3, 2026 | 42.29% |
| Jan 2, 2026 | 40.45% |
| Oct 3, 2025 | 40.81% |
| Jul 4, 2025 | 38.88% |
| Apr 4, 2025 | 34.96% |
| Jan 3, 2025 | 30.14% |
| Sep 27, 2024 | 26.60% |
| Jun 28, 2024 | 44.45% |
| Mar 29, 2024 | 8.43% |
| Dec 29, 2023 | 18.41% |
| Sep 29, 2023 | -2.39% |
| Jun 30, 2023 | 17.85% |
| Mar 31, 2023 | 8.73% |
| Dec 30, 2022 | -9.94% |
| Sep 30, 2022 | 21.44% |
| Jul 1, 2022 | 21.10% |
| Apr 1, 2022 | 24.65% |
| Oct 1, 2021 | 17.18% |
| Jul 2, 2021 | 32.89% |
API Access
Exelixis EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=EXEL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "EXEL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=EXEL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();